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1. INTRODUCTION 
Clostridium difficile is a gram positive, spore forming anaerobe with the ability to 
survive for long periods in the environment. It is responsible for nosocomial diarrhoea 
and is a major healthcare burden worldwide. Transmission occurs via the faecal-oral route 
due to poor hygiene or as a consequence of antibiotic treatment in hospital patients. 
Currently, it is only susceptible to three marketed antibiotics and other treatment options 
include faecal transplantation and potentially bacteriophages (phages). Possibility of 
treatment failure and high reoccurrence rate has led to an increased interest in 
bacteriophage therapy. Bacteriophages are viruses with narrow host ranges which 
undergo specific phage-bacterial interactions. They are able to lyse C. difficile without 
subsequent dysbiosis of the colon typical of antibiotic treatment. They are self-
amplifying, in that upon infecting C. difficile in the gut they are able to replicate and 
increase in concentration rapidly thereby effectively killing the infecting host population. 
Enteric pathogens such as C. difficile pose a number of challenges for site-specific 
delivery of phages. The highly acidic environment of the upper GI tract renders phages 
inactive prior to reaching the site of infection. Therefore, microencapsulation of phages in 
a pH responsive polymer (Eudragit® S100) using a glass microfluidic device to facilitate 
encapsulation, for colon targeted delivery is proposed here.  
 
 
 
 
 
Figure 1. a) schematic to show the polymer 
release mechanism; b) schematic of the glass capillary microfluidic device for particle generation; 
c) screen shot of droplet formation; d) SEM of phage encapsulated particles.  
 
Eudragit® S100 is a methacrylic acid / methyl methacrylate copolymer, which is 
soluble at the pH of the colon (pH ≥7), making it a suitable encapsulation agent for 
protecting acid-sensitive phages. Dissolution results from dissociation of carboxylic 
groups on the polymer chains at pH above the pKa resulting in electrostatic repulsion of 
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the polymer chains and pH dependent release of the encapsulated phages (Figure 1a). To 
produce phage-encapsulated Eudragit® S100 microparticles a microfluidic glass capillary 
device was used to allow precise control over particle size and shell thickness (Figure 1b). 
 
The aim of the study was to investigate long term stability of the device and develop a 
process for phage encapsulation in core-shell particles. Characterisation of microparticle 
morphology and evaluation of subsequent phage release kinetics was carried out. 
 
2. EXPERIMENTAL 
Core-shell droplets were produced using a two-phase glass capillary device with 
counter-current flow focusing placed on the stage of an inverted microscope. The orifice 
size of the collection capillary was 200 µm (Figs. 1c, 1d). The inner phase was an 
aqueous Eudragit® S100 solution (5% w/v) with phages at 108 PFU ml-1. The outer phase 
consisted of Miglyol 840 with 2% (w/v) polyglycerol polyricinoleate (PGPR) emulsifier 
and 1% (w/v) 4-aminobenzoic acid. The collected particles were cured for 24 h to allow 
adequate exposure to acid in the oil phase. The polymer was precipitated using 4-amino- 
benzoic acid in the continuous phase. Image J software was used to analyse the droplet 
sizes. Scanning electron microscopy (SEM) was used to take images of particles. 
Sorensen’s buffer (NaH2PO4 and Na2HPO4) 0.2 M at pH 7.2 was used to dissolve 
polymeric particles and release phage. Phage enumeration was carried out by the double-
layer agar method. Briefly, 10 µl was removed at time intervals, serially diluted and 
spotted on a lawn of C. difficile on an agar plate. After 24 h anaerobic incubation, plaques 
were counted and recorded as PFU ml-1. 
 
3. RESULTS AND DISCUSSION 
Long term study results showed that the droplet generation was stable for a period of 6 
h without compromising the monodispersity of the droplets. The droplet diameter 
remained fairly constant throughout this period with the coefficient of variation (CV) 
staying below 2%. Initially, the flow of the inner and outer phases (1.2 and 7 ml hr-1 
respectively) was adjusted to achieve a dripping regime for stable droplet formation; 
therefore, stabilization took approximately 45 min before a stable droplet size within a 
narrow size range was achieved. The average diameter of the droplets was 155 µm with a 
mean CV = 0.9 %. This is an important parameter in therapeutic formulations as the size 
of the particles influences the release kinetics of the bioactive agent. Videos were 
recorded for droplet size analysis; Figure 1c shows a shot of the droplet and/or particle 
formation in a glass capillary device. Figure 1d shows SEM images of the different sized 
particles that can be tailored as desired with varying flow rates in a glass capillary device. 
The spherical nature of the particles demonstrates their ability to retain bacteriophages. 
Subsequent analysis showed the release kinetics of the bacteriophage in Sorensen’s buffer 
at pH 7.2. The phage release was observed to be a sudden burst followed by subsequent 
increase over a 6 h period. Burst release would be preferred to ensure a higher 
multiplicity of infection (MOI) which plays a crucial role in reducing bacterial numbers. 
  
4. CONCLUSIONS 
Preliminary results are encouraging showing suitability of pH responsive polymer 
Eudragit® S100 in encapsulating phages for colon targeting. Controlled release in alkaline 
buffer illustrates the promise of using the formulation as an enteric coating for colon 
targeted phage delivery. Future work is planned to control the release kinetics and 
evaluate phage encapsulation yield. 
